Abnormal serum immunofixation patterns following BCMA CAR-T in multiple myeloma

Incorporating BCMA-targeted CAR-T therapy in the frontline treatment of multiple myelomaПодробнее

Prognostic value of ALC following BCMA CAR T-cell therapy in multiple myelomaПодробнее

Biallelic BCMA loss causes anti-BCMA CAR-T resistance in myelomaПодробнее

Anti-BCMA CAR T-cell therapy for multiple myeloma: latest studiesПодробнее

Meta-analysis: anti-BCMA CAR-T in R/R multiple myelomaПодробнее

CAR T-cells in Multiple MyelomaПодробнее

Car T-Cell Therapy & Conjugated BCMA Monoclonal AntibodiesПодробнее

CAR T-Cells Multiple Myeloma: Adam Sperling, MD, PhDПодробнее

CAR T-cell Therapy in Multiple MyelomaПодробнее

Biallelic Loss of BCMA Triggers Resistance to Anti-BCMA CAR T Cell Therapy in Multiple MyelomaПодробнее

BCMA-Directed CAR T-Cell Therapy: OutlookПодробнее

Phase I CRB-402 Study of the BCMA-Targeted CAR T Cell Therapy bb21217 in Pts w/RR Multiple MyelomaПодробнее

Immunotherapy of myeloma: BCMA/SLAMF7 CAR T-cells & BiTEsПодробнее

Promise of GPRC5D-targeted CAR-T therapies in multiple myelomaПодробнее

Clinical activity seen with anti-BCMA CAR T-Cell therapy for heavily pre-treated multiple myelomaПодробнее

CAR T Cells in Multiple MyelomaПодробнее

Multiple Myeloma Precursor Conditions | Overview | Therapeutic InterventionПодробнее

A 2023 Update on CAR-T Therapy in Myeloma with Dr. Craig HofmeisterПодробнее

bb21217: next gen anti-BCMA CAR-T for R/R MMПодробнее